Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Naphazoline hydrochloride 120 microgram/mL eye drops |
Is a |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Naphazoline hydrochloride 120 microgram/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Naphazoline hydrochloride 1 mg/mL eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
naphazolinhydrochlorid 1 mg/ml opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Naphazoline hydrochloride 0.1%wv solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Naphazoline hydrochloride 0.012% eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely naphazoline hydrochloride 200 microgram/1 milliliter conventional release eye solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely naphazoline hydrochloride 300 microgram/1 milliliter conventional release eye solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
antazolinphosphat + naphazolinhydrochlorid 5 mg/0,5 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
naphazolinhydrochlorid + polyvinylalkohol + zinksulfat 0,02 % wt/vol/0,25 % wt/vol/0,25 % wt/vol dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
antazolinphosphat + naphazolinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
naphazolinhydrochlorid + pheniramin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Naphazoline hydrochloride 250 microgram/mL and pheniramine maleate 3 mg/mL eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Naphazoline hydrochloride |
Inferred relationship |
Some |
|
Naphazoline hydrochloride 120 microgram/mL eye drops |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Naphazoline hydrochloride 120 microgram/mL eye drops |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Naphazoline hydrochloride 1 mg/mL eye solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Naphazoline hydrochloride 1 mg/mL eye solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely naphazoline hydrochloride 200 microgram/1 milliliter conventional release eye solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely naphazoline hydrochloride 200 microgram/1 milliliter conventional release eye solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely naphazoline hydrochloride 300 microgram/1 milliliter conventional release eye solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely naphazoline hydrochloride 300 microgram/1 milliliter conventional release eye solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
1 |
Naphazoline hydrochloride 250 microgram/mL and pheniramine maleate 3 mg/mL eye solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
2 |
Naphazoline hydrochloride 250 microgram/mL and pheniramine maleate 3 mg/mL eye solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
2 |
Naphazoline hydrochloride 270 microgram/mL and pheniramine maleate 3.15 mg/mL eye solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
2 |
Naphazoline hydrochloride 270 microgram/mL and pheniramine maleate 3.15 mg/mL eye solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Naphazoline hydrochloride |
Inferred relationship |
Some |
2 |